Stockscreener 앱 받기
39.77
0.05%
0.02
시간 외 거래:
39.77
전일 마감가:
$39.75
열려 있는:
$39.63
하루 거래량:
739.80K
Relative Volume:
0.68
시가총액:
$4.16B
수익:
$7.70M
순이익/손실:
$-465.32M
주가수익비율:
-8.0431
EPS:
-4.9446
순현금흐름:
$-383.68M
1주 성능:
-0.48%
1개월 성능:
+6.08%
6개월 성능:
-9.92%
1년 성능:
+34.09%
1일 변동 폭
$38.99
$40.03
1주일 범위
$38.25
$40.44
52주 변동 폭
$25.83
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
39.77 | 4.16B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-10 | 개시 | Goldman | Neutral |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
CRNX (NASDAQ: CRNX) files Rule 144: 20,900-share exercise, prior 10b5-1 sales - Stock Titan
Insider Sales: CRNX (NASDAQ: CRNX) 4,434-share option sale; Knight 95,074 prior shares - Stock Titan
(CRNX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fed Meeting: Is Crinetics Pharmaceuticals Inc stock a top performer YTD2026 Rallies & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Crinetics Pharmaceuticals Signs Independent Consultant Agreement with Jeff Knight – 8-K Filing Details and XBRL Information - Minichart
Crinetics Pharma chief dev officer sells $3.4m in stock By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Insider Sold Shares Worth $3,415,036, According to a Recent SEC Filing - marketscreener.com
Crinetics (CRNX) COO exercises options and sells 85,163 shares under 10b5-1 - Stock Titan
Jeff Knight exits Crinetics (NASDAQ: CRNX) officer role, stays on under paid consulting deal - Stock Titan
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Sahm
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Brazil ANVISA Filing For PALSONIFY - Sahm
Crinetics Pharmaceuticals to Report Q1 2026 Results on May 7 - National Today
Aug Retail: Whats the beta of Crinetics Pharmaceuticals Inc stock2026 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Insider sale: CRNX (NASDAQ: CRNX) files Form 144 for 9,911 shares on 03/16/2026 - Stock Titan
Crinetics sets May 7 earnings call, business update after close - Stock Titan
Aug Shorts: Is Crinetics Pharmaceuticals Inc a stock for growth or value investors2026 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Future of Pituitary Cancer Market (2026-2033) | Precision - openPR.com
Risk Hedge: Is Crinetics Pharmaceuticals Inc exposed to currency risks2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint - Sahm
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Price performance - Yahoo Finance Australia
Crinetics Pharmaceuticals Inc (6Z4.DU) stock price, news, quote and history - Yahoo Finance UK
Price-Driven Insight from (CRNX) for Rule-Based Strategy - Stock Traders Daily
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More - AOL.com
Crinetics Pharmaceuticals Director Sells Shares - intellectia.ai
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRNX PE Ratio & Valuation, Is CRNX Overvalued - Intellectia AI
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharma Director Stock SaleMarch 2026 Transaction DetailsNews and Statistics - IndexBox
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Crinetics submits application for acromegaly drug in Brazil By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly - Bitget
Vanguard disaggregates holdings; Crinetics (CRNX) parent reports 0 shares - Stock Titan
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly - The Manila Times
Crinetics submits application for acromegaly drug in Brazil - Investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing - globenewswire.com
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - MarketScreener
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):